Advanced search
Publication Cover
Expert Opinion on Therapeutic Targets Volume 9, 2005 - Issue 2
Submit an article Journal homepage
49
Views
5
CrossRef citations to date
0
Altmetric
Review

Targeting epigenetic regulatory mechanisms in cancer chemoprevention

Judith R Fay CCS Associates, 2005 Landings Dr, Mountain View, CA 94043, USA. [email protected]
,
James A Crowell National Cancer Institute, Division of Cancer Prevention, Executive Plaza North, Room 2117, MSC 7322, Bethesda, MD 20892-7322, USA. [email protected]
&
Levy Kopelovich National Cancer Institute, Division of Cancer Prevention, Executive Plaza North, Room 2144, MSC 7322, Bethesda, MD 20892-7322, USA. [email protected]
Pages 315-328 | Published online: 22 Apr 2005

Bibliography

  • KELLOFF GJ: Perspectives on cancer chemoprevention research and drug development. Adv. Cancer Res. (2000) 78:199–334.
  • KOPELOVICH L, HENSON DE, GAZDAR AF et al.: Surrogate anatomic/ functional sites for evaluating cancer risk: Extension of the field effect. Clin. Cancer Res. (1999) 5:3899–3905.
  • HANAHAN D, WEINBERG RA: The hallmarks of cancer. Cell (2000) 100:57–70.
  • FEINBERG AP, TYCKO B: The history of cancer epigenetics. Nat. Rev Cancer (2004) 4:143–153.
  • ••Review of the history of epigenetics andcancer.
  • JONES PA, BAYLIN SB: The fundamental role of epigenetic events in cancer. Nat. Rev Genet. (2002) 3:415–428.
  • ••Review of the basics of epigeneticregulation and changes during tumourigenesis.
  • JOHNSTONE RW: Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer. Nat. Rev Drug Discov. (2002) 1:287–299.
  • MARKS PA, MILLER T, RICHON VM: Histone deacetylases. Curr. Opin. Pharinacol (2003) 3:344–351.
  • HAKE SB, XIAO A, ALLIS CD: Linking the epigenetic `language' of covalent histone modifications to cancer. Br. Cancer (2004) 90:761–769.
  • ••Excellent recent review of the histonecode and its relationship to cancer.
  • HERMAN JG, BAYLIN SB: Gene silencing in cancer in association with promoter hypermethylation. N Engl. I Med. (2003) 349:2042–2054.
  • FEINBERG AP, VOGELSTEIN B: Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature (1983) 301:89–92.
  • ••First demonstration of hypomethylationin cancer.
  • GAMA-SOSA MA, SLAGEL VA, TREWYN RW et al: The 5-methylcytosine content of DNA from human tumors. Nucleic Acids Res. (1983) 11:6883–6894.
  • GOELZ SE, VOGELSTEIN B, HAMILTON SR, FEINBERG AP: Hypomethylation of DNA from benign and malignant human colon neoplasms. Science (1985) 228:187–190.
  • EHRLICH M: DNA methylation in cancer: Too much, but also too little. Oncogene (2002) 21:5400–5413.
  • ••In-depth discussion of potentialconsequences of DNA hypomethylation In cancer.
  • COSTELLO JF, FRUHWALD MC, SMIRAGLIA DJ et al: Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat. Genet. (2000) 25:132–138.
  • KOPELOVICH L, CROWELL JA, FAY JR: The epigenome as a target for cancer chemoprevention. Nati Cancer Inst. (2003) 95:1747–1757.
  • ••Recent comprehensive review of epigeneticchanges in precancerous lesions.
  • NAKAGAWA H, NUOVO GJ, ZERVOS EE et al: Age-related hypermethylation of the 5' region of MLHI in normal colonic mucosa is associated with microsatellite-unstable colorectal cancer development. Cancer Res. (2001) 61:6991–6995.
  • PALMISANO WA, DIVINE KK, SACCOMANNO G et al.: Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. (2000) 60:5954–5958.
  • BROOKS JD, WEINSTEIN M, UN X et al.: CG island methylation changes near the CSTPI gene in prostatic intraepithelial neoplasia. Cancer Epidenhol Biomarkers Prey. (1998) 7:531–536.
  • SUTER CM, MARTIN DI, WARD RL: Germline epimutation of MLHI in individuals with multiple cancers. Nat. Genet. (2004) 36:497–501.
  • ••First demonstration that 'epimutation'In germ line of non-imprinted gene can predispose to cancer.
  • EHRLICH M, JIANG G, FIALA E et al: Hypomethylation and hypermethylation of DNA in Wilms tumors. Oncogene (2002) 21:6694–6702.
  • ••Study showing that hypomethylation andhypermethylation are independent events during tumourigenesis.
  • BARIOL C, SUTER C, CHEONG K et al.: The relationship between hypomethylation and CpG island methylation in colorectal neoplasia. Am. J. Patna (2003) 162:1361–1371.
  • VIGUSHIN DM, COOMBES RC: Targeted histone deacetylase inhibition for cancer therapy. Curc Cancer Drug Targets (2004) 4:205–218.
  • •Recent review of histone modifying machinery dysregulation in cancer and HDAC inhibitors as chemotherapeutics.
  • STRAHL BD, ALLIS CD: The language of covalent histone modifications. Nature (2000) 403:41–45.
  • ••Proposal of the 'histone code'.
  • GRIGNANI F, DE MATTEIS S, NERVI Cet al.: Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature (1998) 391:815–818.
  • ZHU P, MARTIN E, MENGWASSER J, SCHLAG P, JANSSEN K-P, GOTTLICHER M: Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell (2004) 5:455–463.
  • ••Demonstration of the critical role ofHDAC2 in colon carcinogenesis.
  • VARAMBALLY S, DHANASEKARAN SM, ZHOU M et al.: The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (2002) 419:624–629.
  • KLEER CG, CAO Q, VARAMBALLY S et al.: EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl. Acad. Sci. USA (2003) 100:11606–11611.
  • NGUYEN CT, WEISENBERGER DJ, VELICESCU M et al: Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2'-deoxycytidine. Cancer Res. (2002) 62:6456–6461.
  • •First demonstration of aberrant histone lysine methylation at silenced tumour suppressor loci in tumour cells.
  • NELSON WG, DE MARZO AM, DEWEESE TL et al: Preneoplastic prostate lesions: An opportunity for prostate cancer prevention. Ann. N.11.- Acad. Sci. (2001) 952:135–144.
  • JERONIMO C, VARZIM G, HENRIQUE R et al: II05Vpolymorphism and promoter methylation of the CSTPI gene in prostate adenocarcinoma. Cancer Epidenhol Biomarkers Prey. (2002) 11:445–450.
  • YAMANAKA M, WATANABE M, YAMADA Y et al.: Altered methylation of multiple genes in carcinogenesis of the prostate. Int. J. Cancer (2003) 106:382–387.
  • KANG GH, LEES, LEE HJ, HWANG KS: Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia. J. Pathol (2004) 202:233–240.
  • WOODSON K, GILLESPIE J, HANSON J et al: Heterogeneous gene methylation patterns among pm-invasive and cancerous lesions of the prostate: A histopathologic study of whole mount prostate specimens. Prostate (2004) 60:25–31.
  • SONG JZ, STIRZAKER C, HARRISON J, MELKI JR, CLARK SJ: Hypermethylation trigger of the glutathione-S-transferase gene (GSTP/) in prostate cancer cells. Oncogene (2002) 21:1048–1061.
  • GONZALGO ML, PAVLOVICH CP, LEE SM, NELSON WG: Prostate cancer detection by CSTPI methylation analysis of postbiopsy urine specimens. Clia Cancer Res. (2003) 9:2673–2677.
  • GOESSL C, MULLER M, HEICAPPELL R et al: DNA-based detection of prostate cancer in urine after prostatic massage. Urology (2001) 58:335–338.
  • JERONIMO C, HENRIQUE R, HOQUE MO et al: Quantitative 14RI32 hypermethylation: A promising prostate cancer marker. Clin. Cancer Res. (2004) 10:4010–4014.
  • HALKIDOU K, GAUGHAN L, COOKS, LEUNG HY, NEAL DE, ROBSON CN: Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate (2004) 59:177–189.
  • FU M, WANG C, ZHANG X, PESTELL RG: Acetylation of nuclear receptors in cellular growth and apoptosis. Biochem. Pharmacol. (2004) 68:1199–1208.
  • HONG H, KAO C, JENG MH et al.: Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status. Cancer (2004) 101:83–89.
  • KONDO Y, ISSA J-PJ: Epigenetic changesin colorectal cancer. Cancer Metastasis Rev (2004) 23:29–39.
  • •Recent review of epigenetic dysregulation In colon carcinogenesis.
  • AHUJA N, LI Q, MOHAN AL, BAYLIN SB, ISSA J-PJ: Aging and DNA methylation in colorectal mucosa and cancer. Cancer Res. (1998) 58:5489–5494.
  • •Contribution of aging to methylation changes in colon cancer.
  • CHAN AO, BROADDUS RR, HOULIHAN PS, ISSA J-PJ, HAMILTON SR, RASHID A: CpG island methylation in aberrant crypt foci of the colorectum. Am. Patna (2002) 160:1823–1830.
  • HSIEH C-J, KLUMP B, HOLZMANN K, BORCHARD F, GREGOR M, PORSCHEN R: Hypermethylation of the p MINI"' promoter in colectomy specimens of patients with long-standing and extensive ulcerative colitis. Cancer Res. (1998) 58:3942–3945.
  • HAWKINS NJ, WARD RU: Sporadic colorectal cancers with microsatellite instability and their possible origin in hyperplastic polyps and serrated adenomas. J. Natl. Cancer Inst. (2001) 93:1307–1313.
  • JASS JR, YOUNG J, LEGGETT BA: Evolution of colorectal cancer: Change of pace and change of direction. Castroenterol Hepatol (2002) 17:17–26.
  • SUZUKI H, WATKINS DN, JAIR K-W et al: Epigenetic inactivation of SFRPgenes allows constitutive WNT signaling in colorectal cancer. Nat. Genet. (2004) 36:417–422.
  • FEARNHEAD NS, BRITTON MP, BODMER WF: The ABC of APC. Hum. Mol. Genet. (2001) 10:721–733.
  • LAIRD PW, JACKSON-GRUSBY L, FAZELI A et al.: Suppression of intestinal neoplasia by DNA hypomethylation. Ce//(1995) 81:197–205.
  • ••First demonstration of chemopreventiveeffects of DNMT inhibitors in animal models.
  • EADS CA, NICKEL AE, LAIRD PW: Complete genetic suppression of polyp formation and reduction of CpG-island hypermethylation in April6n4 Dnmt hypomorphic mice. Cancer Res. (2002) 62:1296–1299.
  • TRINH BN, LONG TI, NICKEL AE, SHIBATA D, LAIRD PW: DNA methyltransferase deficiency modifies cancer susceptibility in mice lacking DNA mismatch repair. Mol. Cell Biol. (2002) 22:2906–2917.
  • CUI H, CRUZ-CORREA M, GIARDIELLO FM et al.: Loss of IGF2 imprinting: A potential marker of colorectal cancer risk. Science (2003) 299: 1753-1755.
  • •Loss of imprinting may play a causal role In colon cancer.
  • WIDSCHWENDTER M, JONES PA: DNA methylation and breast carcinogenesis. Oncogene (2002) 21:5462–5482.
  • •Comprehensive review of DNA methylation changes in breast cancer.
  • LEHMANN U, LANGER F, FEIST H, GLOCKNER S, HASEMEIER B, KREIPE H: Quantitative assessment of promoter hypermethylation during breast cancer development. Am. J. Pathol. (2002) 160:605–612.
  • HONORIO S, AGATHANGGELOU A, SCHUERMANN M et al.: Detection of RASSFIA aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients. Oncogene (2003) 22:147–150.
  • FACKLER MJ, MCVEIGH M, EVRON Eet al.: DNA methylation of RASSFIA, HIN-I, 14R-f3, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma. Int. J. Cancer (2003) 107:970–975.
  • PU RT, LAITALA LE, ALLI PM, FACKLER MJ, SUKUMAR S, CLARK DP: Methylation profiling of benign and malignant breast lesions and its application to cytopathology. Mod. Pathol. (2003) 16:1095–1101.
  • KRASSENSTEIN R, SAUTER E, DULAIMI E et al.: Detection of breast cancer in nipple aspirate fluid by CpG island hypermethylation. Clin. Cancer Res. (2004) 10:28–32.
  • EVRON E, DOOLEY WC, UMBRICHT CB et al.: Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. Lancet (2001) 357:1335–1336.
  • •Detection of methylated alleles non-invasively predicted subsequent breast cancer development.
  • LEHMANN U, CELIKKAYA G, HASEMEIER B, LANGER F, KREIPE H: Promoter hypermethylation of the death-associated protein kinase gene in breast cancer is associated with the invasive lobular subtype. Cancer Res. (2002) 62:6634–6638.
  • FUQUA SAW, WILTSCHKE C, ZHANG QX et al.: A hypersensitive estrogen receptor-a mutation in premalignant breast lesions. Cancer Res. (2000) 60:4026–4029.
  • MCMANUS DT, OLARU A, MELTZER SJ: Biomarkers of esophageal adenocarcinoma and Barrett's esophagus. Cancer Res. (2004) 64:1561–1569.
  • BIAN Y-S, OSTERHELD M-C, FONTOLLIET C, BOSMAN FT, BENHATTAR J: p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett's esophagus. Gastroenterology (2002) 122:1113–1121.
  • KLUMP B, HSIEH C-J, HOLZMANN K, GREGOR M, PORSCHEN R: Hypermethylation of the CDKN2/p16 promoter during neoplastic progression in Barrett's esophagus. Gastroenterology (1998) 115:1381–1386.
  • MALEY CC, GALIPEAU PC, LI X, SANCHEZ CA, PAULSON TG, REID BJ: Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus. Cancer Res. (2004) 64:3414–3427.
  • •Hypermethylation of tumour suppressor affords selective advantage for precancerous cell growth.
  • NIE Y, LIAO J, ZHAO X, SONG Y, YANG G-Y, WANG L-D, YANG CS: Detection of multiple gene hypermethylation in the development of esophageal squamous cell carcinoma. Carcinogenesis (2002) 23:1713–1720.
  • EADS CA, LORD RV, WICKRAMASINGHE K et al.: Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res. (2001) 61:3410–3418.
  • BELINSKY SA, NIKULA KJ, PALMISANO WA et al.: Aberrant methylation of pi61NK4a is an early event in lung cancer and a potential biomarker for early diagnosis. Proc. Nati Acad. Li. USA (1998) 95:11891–11896.
  • •First demonstration that hypermethylation of tumour suppressor gene is an early event In lung cancer development.
  • LAMY A, SESBOUE R, BOURGUIGNON J et al.: Aberrant methylation of the CDKN2a/p16INK4a gene promoter region in preinvasive bronchial lesions: A prospective study in high-risk patients without invasive cancer. Int. J. Cancer (2002) 100:189–193.
  • BELINSKY SA, PALMISANO WA, GILLILAND FD et al.: Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res. (2002) 62:2370–2377.
  • SORIA J-C, RODRIGUEZ M, LIU DD, LEE JJ, HONG WK, MAO L: Aberrant promoter methylation of multiple genes in bronchial brush samples from former cigarette smokers. Cancer Res. (2002) 62:351–355.
  • KERSTING M, FRIEDL C, KRAUS A, BEHN M, PANKOW W, SCHUERMANN M: Differential frequencies of p/6/Nma promoter hypermethylation, p53mutation, and K-ras mutation in exfoliative material mark the development of lung cancer in symptomatic chronic smokers. J. Clin. Oncol. (2000) 18:3221–3229.
  • GUO M, HOUSE MG, HOOKER C et al.: Promoter hypermethylation of resected bronchial margins: A field defect of changes? Chu. Cancer Res. (2004) 10:5131–5136.
  • ZOCHBAUER-MULLER S, LAM S, TOYOOKA S et al.: Aberrant methylation of multiple genes in the upper aerodigestive tract epithelium of heavy smokers. Int. J. Cancer (2003) 107:612–616.
  • PULLING LC,VUILLEMENOT BR, HUTT JA, DEVEREUX TR, BELINSKY SA: Aberrant promoter hypermethylation of the death-associated protein kinase gene is early and frequent in murine lung tumors induced by cigarette smoke and tobacco carcinogens. Cancer Res. (2004) 64:3844–3848.
  • VUILLEMENOT BR, PULLING LC, PALMISANO WA, HUTT JA, BELINSKY SA: Carcinogen exposure differentially modulates RAR-13 promoter hypermethylation, an early and frequent event in mouse lung carcinogenesis. Carciriogenesis (2004) 25:623–629.
  • BELINSKY SA, KLINGE DM, STIDLEY CA et al.: Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Res. (2003) 63:7089–7093.
  • LAWRENCE LW: Refractory anemia and the myelodysplastic syndromes. Clin. Lab. ScL (2004) 17: 178–186.
  • UCHIDA T, KINOSHITA T, NAGAI H et al.: Hypermethylation of the pI5h11K4B gene in myelodysplastic syndromes. Blood (1997) 90:1403–1409.
  • BRUECKNER B, LYKO F: DNA methyltransferase inhibitors: old and new drugs for an epigenetic cancer therapy. Trends Pharmacol Sci. (2004) 25:551–554.
  • DASKALAKIS M, NGUYEN TT, NGUYEN C et al: Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment. Blood (2002) 100:2957–2964.
  • ISSA JP, GARCIA-MANERO G, GILES FJ et al.: Phase I study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood (2004) 103: 1635-1640.
  • LEES, LEE HJ, KIM J-H, LEE H-S, JANG JJ, KANG GH: Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am. Pathol (2003) 163:1371–1378.
  • CHILES MC, Al L, ZUO C, FAN C-Y, SMOLLER BR: E-cadherin promoter hypermethylation in preneoplastic and neoplastic skin lesions. Mod. Pathol (2003) 16:1014–1018.
  • CHRISTMAN JK: 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: Mechanistic studies and their implications for cancer therapy. Oncogene (2002) 21:5483–5495.
  • ••Excellent review of mechanism ofaction of DNMT inhibitors.
  • Y00 CB, CHENG JC, JONES PA: Zebularine: a new drug for epigenetic therapy. Biochem Soc. Trans. (2004) 32(Pt 6):910–912.
  • GIUS D, CUI H, BRADBURY CM et al: Distinct effects on gene expression of chemical and genetic manipulation of the cancer epigenome revealed by a multimodality approach. Cancer Cell (2004) 6:361–371.
  • ••New study examining global effects ongene expression of pharmacological and genetic manipulation of the epigenome.
  • JOTTERMANN R, LI E, JAENISCH R: Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc. Natl. Acad. Sci. USA (1994) 91:11797–11801.
  • SZYF M: Targeting DNA methylation in cancer. Ageing Res. Rev (2003) 2:299–328.
  • CHENG JC, MATSEN CB, GONZALES FA et al.: Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J. Natl. Cancer Inst. (2003) 95:399–409.
  • CHENG JC, WEISENBERGER DJ, GONZALES FA et al.: Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol. Cell. Biol. (2004) 24:1270–1278.
  • CHENG JC, Y00 CB, WEISENBERGER DJ et al.: Preferential response of cancer cells to zebularine. Cancer Cell (2004) 6:151–158.
  • LIN X, ASGARI K, PUTZI MJ et al: Reversal of GSTPI CpG island hypermethylation and reactivation of pi-class glutathione Stransferase (GSTP1) expression in human prostate cancer cells by treatment with procainamide. Cancer Res. (2001) 61:8611–8616.
  • VILLAR-GAREA A, FRAGA MF, ESPADA J, ESTELLER M: Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. Cancer Res. (2003) 63:4984–4989.
  • DENG C, LU Q, ZHANG Z, RAO T, ATTWOOD J, YUNG R, RICHARDSON B: Hydralazine may induce autoimmunity by inhibiting extracellular signal-regulated kinase pathway signaling. Arthritis Rheum. (2003) 48:746–756.
  • PINA IC, GAUTSCHI JT, WANG GY et al: Psammaplins from the sponge Pseudoceratina purpurea: Inhibition of both histone deacetylase and DNA methyltransferase. I. Org. Chem (2003) 68:3866–3873.
  • FANG MZ, WANG Y, Al N et al: Tea polyphenol 0-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res. (2003) 63:7563–7570.
  • •Study demonstrating DNMT inhibition may contribute to biological activity of established chemopreventive agent.
  • VILLAR-GAREA A, ESTELLER M: DNA demethylating agents and chromatin-remodelling drugs: which, how and why? Curr. Drug Metab. (2003) 4:11–31.
  • DAVIS AJ, GELMON KA, SIU LL et al: Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks. Invest. New Drugs. (2003) 21:85–97.
  • ROBERT M-F, MORIN S, BEAULIEU N et al: DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat. Genet. (2003) 33:61–65.
  • KIM MS, KWON HJ, LEE YM et al: Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat. Med. (2001) 7:437–443.
  • JOHNSTONE RW, LICHT JD: Histone deacetylase inhibitors in cancer therapy: Is transcription the primary target? Cancer Cell (2003) 4:13–18.
  • ••Interesting discussion of possiblealternative mechanism of action of HDAC inhibitors.
  • ROSATO RR, GRANT S: Histone deacetylase inhibitors in clinical development. Expert Opin. Investig. Drugs. (2004) 13:21–38.
  • DETICH N, BOVENZI V, SZYF M: Valproate induces replication-independent active DNA demethylation. Biol. Chem. (2003) 278:27586–27592.
  • LU Q, YANG YT, CHEN CS et al: Zn2'-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. Med. Chem. (2004) 47:467–474.
  • PARK JH, JUNG Y, KIM TY et al: Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation. Clin. Cancer Res. (2004) 10:5271–5281.
  • •• Study showing biological action ofisoform selective HDAC inhibitors.
  • ZELENT A, WAXMAN S, CARDUCCI M, WRIGHT J, ZWEIBEL J, GORE SD: State of the translational science: summary of Baltimore workshop on gene re-expression as a therapeutic target in cancer; January 2003. Clin. Cancer Res. (2004) 10:4622–4629.
  • DAVIS CD, UTHUS EO: Dietary selenite and azadeoxycytidine treatments affect dimethylhydrazine-induced aberrant crypt formation in rat colon and DNA methylation in HT-29 cells. J. Num. (2002) 132:292–297.
  • LANTRY LE, ZHANG Z, CRIST KA et al: 5-Aza-2' -decocycytidine is chemopreventive in a 4-(methyl-nitrosamino) 1 (3 pyridy6-1-butanone-induced primary mouse lung tumor model. Carcinogenesis (1999) 20:343–346.
  • FIALA ES, STARETZ ME, PANDYA GA, EL-BAYOUMY K, HAMILTON SR: Inhibition of DNA cytosine methyltransferase by chemopreventive selenium compounds, determined by an improved assay for DNA cytosine methyltransferase and DNA cytosine methylation. Carcinogenesis (1998) 19:597–604.
  • COHEN LA, AMIN S, MARKS PA, RIFKIND RA, DESAI D, RICHON VM: Chemoprevention of carcinogen-induced mammary tumorigenesis by hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA). Anti-Cancer Res. (1999) 19:4999–5005.
  • •First demonstration of chemopreventive action of HDAC inhibitors in animal models.
  • COHEN LA, MARKS PA, RIFKIND RA et al.: Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumours. Anti-Cancer Res. (2002) 22:1497–1504.
  • DESAI, D, DAS A, COHEN L, EL-BAYOUMY K, AMIN S: Chemopreventive efficacy of suberoylanilide hydroxamic acid (SAHA) against 4-(methylnitrosamino) I (3 pyridy0-1-butanone (NNK)-induced lung tumorigenesis in female A/J mice. Anti-Cancer Res. (2003) 23:499–503.
  • WARGOVICH MJ, JIMENEZ A, MCKEE K et al: Efficacy of potential chemopreventive agents on rat colon aberrant crypt formation and progression. Carcinogenesis (2000) 21:1149–1155.
  • WARGOVICH MJ, CHEN C.D, JIMENEZ A et al.: Aberrant crypts as a biomarker for colon cancer: Evaluation of potential chemopreventive agents in the rat. Cancer Epidenhol Biomarkers Prey. (1996) 5:355–360.
  • WEI M, WANIBUCHI H, MORIMURA K et al.: Lack of preventive efficacy of FK228, a histone deacetylase inhibitor, against Nbutyl-N-(4-hydroxybuty6 nitrosamine-induced urinary bladder carcinogenesis in p534 and p534' mice. Anti-Cancer Res. (2004) 24:785–790.
  • MYZAK MC, KARPLUS PA, CHUNG FL, DASHWOOD RH: A novel mechanism of chemoprotection by sulforaphane: Inhibition of histone deacetylase. Cancer Res. (2004) 64:5767–5774.
  • CAMERON EE, BACHMAN KE, MYOHANEN S, HERMAN JG, BAYLIN SB: Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. (1999) 21:103–107.
  • •First demonstration of synergy between DNMT and HDAC inhibitors.
  • ZHU W-G, OTTERSON GA: The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Curt: Med. Chem. Anti-Cancer Agents (2003) 3:187–199.
  • WIDSCHWENDTER M, JONES PA: The potential prognostic, predictive, and therapeutic values of DNA methylation in cancer: Commentary Re: J Kwong et al., Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. Clin. Cancer Res. (2002) 8:131-137 and H-Z Zou et al. Clin. Cancer Res. (2002) 8:17–21.
  • FERRARA FE FAZI F, BIANCHINI A et al.: Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res. (2001) 61:2–7.
  • COTE S, MOMPARLER RL: Activation of the retinoic acid receptor beta gene by 5-aza-2'-deoxycytidine in human DLD-1 colon carcinoma cells. Anticancer Drugs (1997) 8:56–61.
  • WIDSCHWENDTER M, BERGER J, HERMANN M et al.: Methylation and silencing of the retinoic acid receptor-132 gene in beast cancer. J. Nati Cancer Inst. (2000) 92:826–832.
  • GARBER K. Synthetic lethality: killing cancer with cancer. J. Nati Cancer Inst. (2000) 94:1666–1668.
  • KOZAR K, KAMINSKI R, SWITAJ T et al: Interleukin 12-based immunotherapy improves the antitumor effectiveness of a low-dose 5-Aza-2'-deoxycitidine treatment in L1210 leukemia and B16F10 melanoma models in mice. Clin. Cancer Res. (2003) 9:3124–3133.
  • LIANG G, GONZALES FA, JONES PA, ORNTOFT TF, THYKJAER T: Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2'-deoxycytidine. Cancer Res. (2002) 62:961–966.
  • PAKNESHAN P, SZYF M, FARIAS-EISNER R, RABBANI SA: Reversal of the hypomethylation status of urokinase (uPA) promoter blocks breast cancer growth and metastasis. J. Biol. Chem. (2004) 279:31735–31744.
  • GAUDET F, HODGSON JG, EDEN A et al: Induction of tumors in mice by genomic hypomethylation. Science (2003) 300:489–492.
  • •DNA hypomethylation linked to tumour enhancement in animal model.
  • EDEN A, GAUDET F, WAGHMARE A, JAENISCH R: Chromosomal instability and tumors promoted by DNA hypomethylation. Science (2003) 300:455.
  • •DNA hypomethylation linked to tumour enhancement in animal model.
  • RHEE I, BACHMAN KE, PARK BH et al: DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature (2002). 416:552–556.
  • TING AH, JAIR K-W, SUZUKI H, YEN R-WC, BAYLIN SB, SCHUEBEL KE: CpG island hypermethylation is maintained in human colorectal cancer cells after RNAi-mediated depletion of DNMT1. Nat. Genet. (2004) 36:582–584.
  • LAIRD PW: The power and the promise of DNA methylation markers. Nat. Rev Cancer (2003) 3:253–266.
  • ••Excellent review of the potential uses ofDNA methylation markers in clinical settings.

Websites

  • hdp://www.cancengovklinicaltrials. US National Cancer Institute, National Institutes of Health. Links to clinical trials (2004).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.